Skip to main content
Fig. 2 | BMC Infectious Diseases

Fig. 2

From: Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use

Fig. 2

Minimum time until inadvertent trivalent oral poliovirus vaccine (tOPV) use in a supplemental immunization activity (SIA) leads to a serotype 2 vaccine-derived poliovirus (cVDPV2) outbreak (Analysis I) a in a hypothetical population with no seasonality in the basic reproduction number (R0) b in realistic populations with seasonality

Back to article page